Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis

William Hinton1,2, Michael D. Feher1, Neil Munro2, Mark Joy1 and Simon de Lusignan1,3*

Abstract

Background: Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are licenced for initiation for glucose lowering in people with type 2 diabetes (T2DM) with an estimated glomerular filtration rate (eGFR) $\geq$ 60 mL/min/1.73m². However, recent trial data have shown that these medications have renal and cardio-protective effects, even for impaired kidney function. The extent to which trial evidence and updated guidelines have influenced real-world prescribing of SGLT-2is is not known, particularly with co-administration of diuretics.

Methods: We performed a cross-sectional analysis of people with T2DM registered with practices in the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database on the 31st July 2019. We calculated the percentage of people prescribed SGLT-2is according to eGFR categories (< 45, 45–59, and $\geq$ 60 mL/min/1.73m²), with a heart failure diagnosis and stratified by body mass index categories (underweight, normal weight, overweight, obese), and with concomitant prescription of a diuretic. Multilevel logistic regression analysis was performed to determine whether heart failure diagnosis and renal function were associated with SGLT-2i prescribing.

Results: From a population of 242,624 people with T2DM across 419 practices, 11.0% ($n = 26,700$) had been prescribed SGLT-2is. The majority of people initiated SGLT-2is had an eGFR $\geq$ 60 mL/min/1.73m² (93.2%), and 4.3% had a heart failure diagnosis. 9,226 (3.8%) people were prescribed SGLT-2is as an add-on to their diuretic prescription. People in the highest eGFR category ($\geq$ 60 mL/min/1.73m²) were more likely to be prescribed SGLT-2is than those in eGFR lower categories. Overweight (OR 2.05, 95% CI 1.841–2.274) and obese people (OR 3.84, 95% CI 3.472–4.250) were also more likely to be prescribed these medications, whilst use of diuretics (OR 0.74, 95% CI 0.682–0.804) and heart failure (OR 0.81, 95% CI 0.653–0.998) were associated with lower odds of being prescribed SGLT-2is.

Conclusions: Prescribing patterns of SGLT-2is for glucose lowering in T2DM in primary care generally concur with licenced indications according to recommended renal thresholds. A small percentage of people with heart failure were prescribed SGLT-2is for T2DM. An updated analysis is merited should UK National Institute for Health Care and Excellence prescribing guidelines for T2DM be revised to incorporate new data on the benefits for those with reduced renal function or with heart failure.
Keywords: Type 2, Diabetes Mellitus, Heart Failure, Kidney Function Tests, Computerized Medical Record Systems, Sodium-Glucose Transporter 2 Inhibitors

Background
Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are oral glucose-lowering medications, which are now established drugs in the treatment of type 2 diabetes. They improve glycaemic control by preventing reabsorption of glucose through the proximal tubule of the kidney, and inducing glycosuria [1]. The efficacy of SGLT-2is is reduced when renal function declines; this is reflected in the current licence for initiation at an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m^2, and discontinuation < 45 mL/min/1.73 m^2 [2]. However, recent evidence suggests that these medications have both renal and cardio-protective effects in high risk groups, including those with impaired kidney function.

Recent findings from the cardiovascular safety trials specific to SGLT-2is (EMPA-REG OUTCOME, CANVAS Progam, DECLARE-TIMI 58, and VERTIS-CV) showed that in comparison to placebo treated participants with established cardiovascular disease or at high cardiovascular risk, each drug (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin respectively) reduced the risk of hospitalisation for heart failure independently of glucose-lowering [3–6]. Moreover, renal protective effects have been demonstrated for this drug class [7–10]. The European Association for the Study of Diabetes (EASD) and American Diabetes Association (ADA) subsequently updated their guidelines for the use of antihyperglycaemic medication in type 2 diabetes to include SGLT-2is as a second-line therapy in people with a history of heart failure or chronic kidney disease [11]. The exact mechanisms behind these positive findings are yet to be determined, but it has been suggested that SGLT-2is may enhance the effect of loop-diuretics in terms of diuresis and natriuresis [12]. Currently, concomitant use of these drugs isn’t advised due to increased risk of volume depletion [13]. The extent to which trial data and guidelines have influenced prescribing in real-world clinical practice is not known, particularly when used in combination with other medications.

The following study was carried out to explore the clinical characteristics of people with type 2 diabetes prescribed SGLT-2is in an English primary care setting, and to determine whether renal function and heart failure diagnosis are associated with the likelihood of prescribing this medication in the management of type 2 diabetes.

Methods
Aims and objectives
The aims of this study were to identify individuals with type 2 diabetes that have previously been prescribed SGLT-2is. The objectives were to report the prevalence of people prescribed SGLT-2is according to: (1) their renal function; (2) presence of a heart failure diagnosis and body mass index category (BMI); and (3) previous prescriptions of diuretics (concurrently or ever prescribed).

We also explored whether the presence of a heart failure diagnosis and renal function are associated with SGLT-2i prescribing in people with type 2 diabetes after adjusting for known confounders.

Study design and data source
We conducted a cross-sectional analysis using the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database. Data were extracted for adults (≥ 18 years) with type 2 diabetes registered with an Oxford-RCGP RSC practice on the 31st July 2019. The Oxford-RCGP RSC is a primary care sentinel network of volunteer practices distributed throughout England, and comprises a nationally representative sample of patients [14].

In the UK, primary care management of type 2 diabetes is undertaken through general practices with GP and nurse support. Prescribing recommendations for the management of type 2 diabetes in the UK follows the National Institute for Health Care and Excellence (NICE) guidelines, which covers England and Wales, whilst Scotland has the Scottish Intercollegiate Guidelines Network (SIGN) guidelines, which are the recommended standards of care for primary care physicians within the National Health Service of the UK [15, 16].

UK primary care records have been computerised for over twenty years [17]; data are recorded using clinical codes and free-text. Clinical codes are derived from the Read classification [18], which includes codes for diagnoses, therapies, and processes of care. The Read classification was recently replaced by the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) [19]. Data completeness of the Oxford-RCGP RSC database is high [14, 20], which is largely due to the Quality and Outcomes Framework, a pay-for-performance incentive scheme that has been in place since 2004, to encourage improved coding and management of chronic diseases [21]. The planned methods for this study have previously been described [22].
Study population
Using the Oxford-RCGP RSC database, we identified people with type 2 diabetes using a comprehensive two-step ontological-based approach [20]. The first step identifies all people with diabetes using diagnostic codes, blood glucose test results, and diabetes medications. In step 2, people were categorised according to diabetes type via a seven-step algorithm that considers diagnosis codes, medications, BMI, and age at first insulin prescription.

Renal function and heart failure
To determine renal function, we used eGFR values. The eGFR measurements were computed using a previously described ontological method, which uses a minimum of two serum creatinine values recorded at least 90 days apart [23]. Heart failure was identified by searching for codes to indicate the presence of the condition (Additional file 1: Appendix 1).

Statistical analysis
Within the type 2 diabetes cohort, we calculated the prevalence of people with at least one previous prescription for an SGLT-2i, and compared their clinical characteristics (age, gender, ethnicity, socioeconomic status, and duration of diabetes) with the rest of the type 2 diabetes population. Ethnicity was categorised into five major groups (White, Asian, Black, Mixed, and Other), which were defined according to the official UK ethnicity categories by the Office for National Statistics [24]. An established ontological method was also applied to improve data capture for ethnicity. This takes into account recorded ethnicity and language spoken that may infer ethnicity [25]. To determine socioeconomic status, postcodes of individuals in the database were assigned Index of Multiple of Deprivation (IMD) scores, which were converted into categorical variables, quintiles which ranged from 1 (most deprived) to 5 (least deprived) [26]. This conversion process occurs at the point of data extraction, with individual postcodes subsequently removed to maintain pseudonymisation.

The subgroup of people prescribed SGLT-2is were then stratified according to their renal function, and the proportions in each eGFR category (<45, 45–59, and ≥ 60 mL/min/1.73m²) were calculated. Within the same subgroup, we compared BMI categories (underweight: <18.5 kg/m²; normal weight: 18.5–24.9; overweight: 25.0–29.9; obese: ≥ 30) of people with heart failure to those without. We used eGFR and BMI values closest to the first the SGLT-2i prescription. The proportion of people prescribed SGLT-2is as an add-on to diuretic therapy (loop diuretics, potassium sparing diuretics, and thiazides) or after discontinuation were also calculated. These summary statistics were reported using counts and percentages for categorical data, whilst means [with standard deviation SD] were used to describe continuous data.

To investigate whether heart failure and renal function were associated with SGLT-2i prescribing, we performed a multilevel logistic regression analysis, with clustering to account for variability at the practice level. This was a complete case analysis. The model was adjusted for age, gender, ethnicity, IMD quintile, BMI, systolic blood pressure, glycated haemoglobin (HbA1c), presence of cardiovascular disease (defined as one or more codes for myocardial infarction, angina, atrial fibrillation, stroke, and peripheral artery disease), and use of diuretics. Exposures and covariates were defined as the closest recording (in the individual’s medical record) up to two years after diagnosis of diabetes. Individuals that had previously been prescribed an SGLT-2i within two years after diagnosis of diabetes were excluded from this analysis. Odds ratios (OR) with 95% confidence intervals (CI), and P values were reported for each exposure variable. All analyses were performed in R statistical software version 3.5.3.

Sensitivity analysis
As a sensitivity analysis, we re-ran the multilevel logistic regression model after performing multiple imputation. Due to the complexities of trying to impute missing data for ethnicity (data that are not missing at random in primary care) [27], we assigned these data to the white ethnic category. We used predictive mean matching for our imputation method for ten simulated models. The coefficient estimates were then pooled according to Rubin’s rules [28].

Results
The Oxford-RCGP RSC network comprised 3,372,309 adults across 419 practices at the time of data extraction (31st July 2019). Within this population, we identified 242,624 (7.2%) people with type 2 diabetes. Of these, 26,700 (11.0%) had previously been prescribed at least one SGLT-2i. People prescribed SGLT-2is were younger compared to those not prescribed this drug (Table 1), but a higher proportion had been living with diabetes for five or more years (72.8 vs. 66.6%).

The vast majority of people initiated SGLT-2is had an eGFR ≥ 60 mL/min/1.73m² (93.2%), whilst only 463 (1.7%) people had an eGFR < 60 at initiation (Table 2). 1157 (4.3%) people prescribed SGLT-2is with type 2 diabetes had heart failure; the majority of this group were overweight or obese (Table 3). Approximately two fifths of people with type 2 diabetes were prescribed diuretics (n = 104,524; 43.1%), whilst 9226 (3.8%) people were
initiated on an SGLT-2i as an add-on therapy to their diuretic prescription.

In the multilevel logistic regression analysis (N = 239,719), SGLT-2is were more likely to be prescribed in males than females (Table 4). The odds of being prescribed this drug increased by 1.03 (95% CI 1.029–1.031; p < 0.001) per unit increase in HbA1c (mmol/mol). Similarly, as BMI increased, the likelihood of being prescribed SGLT-2is grew; the OR was lower for people in the underweight category compared to those of normal weight, but higher in those that were overweight, and higher still, in those in the obese category (Table 4 and Additional file 2: Figure S1).

In terms of renal function, people with an eGFR < 60 mL/min/1.73m² were less likely to be prescribed SGLT-2is than those with an eGFR ≥ 60 mL/min/1.73m². The odds of being prescribed SGLT-2is were lower in people with heart failure, albeit this association was only just significant (OR 0.81, 95% CI 0.653–0.998; p = 0.048). The presence of cardiovascular disease was also associated with reduced odds of being prescribed SGLT-2is, as were increasing age, use of diuretics, and being of Asian or Black ethnicity compared to White ethnicity (Table 4 and Additional file 2: Figure S1). No association was found between socioeconomic status (IMD Quintile) and SGLT-2i prescribing, and there did not appear to be a clear association for systolic blood pressure (OR 1.00, 95% CI 0.996–0.999; p = 0.001).

The sensitivity analysis of the imputed data reflected these findings, although people of Asian ethnicity had higher odds of being prescribed SGLT-2is than people of White ethnicity (Additional file 2: Table S1; Figure S2).

**Discussion**

This cross-sectional study explored the clinical characteristics of people with type 2 diabetes in an English primary care setting, with a focus on renal function and heart failure as factors associated with a prescription for SGLT-2i. Our findings demonstrated that SGLT-2is are prescribed in about one in ten people with type 2 diabetes. In the vast majority of cases, SGLT-2is were prescribed in people with an eGFR ≥ 60 mL/min/1.73m², whilst around a twentieth of this cohort had heart failure and they were...
mostly overweight or obese. The characteristics of people prescribed these drugs were similar to the wider type 2 diabetes population, but they were younger (by ~6.8 years) and had a longer duration of diabetes (duration ≥5 years: 72.8 vs 66.6%). In addition, individuals were less likely to be prescribed an SGLT-2i if they had previously been prescribed a diuretic.

High BMI appears to be a key driver for SGLT-2i prescribing in people with type 2 diabetes regardless of the presence of heart failure. The weight lowering properties of these drugs are well known, since calories are lost in the glucose when excreted in the urine, and reflect change in body weight [29]. Results from meta-analyses of pooled data from clinical trials demonstrated that participants treated with SGLT-2is lost significantly more weight than those treated with placebo or other glucose-lowering drugs (metformin, sulphonylureas, and dipeptidyl peptidase 4 inhibitors) [30, 31]. Our findings therefore, reflect that clinicians are prescribing according to these established findings.

Similarly, renal function influenced propensity to prescribe SGLT-2is. The current prescribing recommendations for all SGLT-2is are determined by renal function categories of eGFR based upon registration trial data. There has been some evidence indicating that low eGFR thresholds are linked to reduced glucose lowering efficacy [32], which further supports the location of action of these drugs at the renal tubule level. Again, our results reflect that prescribing in real-world clinical practice is in accordance with guidelines. However, data from recent drug safety trials suggest that people with impaired renal function may benefit from SGLT-2i therapy.

In the SGLT-2i cardiovascular outcome trials, exploratory analyses of people with established cardiovascular disease or at high cardiovascular risk, showed that SGLT-2is delayed the progression of kidney disease and renal events compared to placebo in people with an eGFR as low as 30 mL/min/1.73m² [4, 5, 8–10]. More recently, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that compared to placebo, canagliflozin reduced the relative risk of kidney failure by 30% in participants with comorbid chronic kidney disease and type 2 diabetes [33]. In response to these findings, the licence for canagliflozin was recently updated for people with diabetic kidney disease, with drug prescribing at an eGFR ≥30 mL/min/1.73m² [34, 35]. Whilst other SGLT-2is are not currently licensed for initiation in people with an eGFR <60 mL/min/1.73m² and for continuation in those with an eGFR <45 mL/min/1.73m² [2], the emerging evidence that SGLT-2is have reno-protective effects in people impaired renal function implies that these drugs can be used to treat people with chronic kidney disease [36].

When considering the presence of heart failure in people prescribed SGLT-2is, this was lower than the prevalence of heart failure in the broader type 2 diabetes population (4.3 and 8.1% respectively). Moreover, our analysis showed that heart failure was associated with reduced likelihood of being prescribed SGLT-2is. This finding is slightly surprising given that each SGLT-2i drug reduced the risk of heart failure events compared to placebo-controlled participants in the cardiovascular outcome trials [3–6]. Yet this may reflect the earlier

### Table 4 Prescribing of SGLT-2is in type 2 diabetes; multilevel logistic regression model (clustered at the practice level)

| Characteristic       | OR   | 95% CI   | p-value |
|----------------------|------|----------|---------|
| Age (years)          | 0.98 | 0.975–0.979 | <0.001 |
| Gender               |      |          |         |
| Female               | 1.00 | [Reference] |        |
| Male                 | 1.13 | 1.083–1.185 | <0.001 |
| Ethnicity            |      |          |         |
| White                | 1.00 | [Reference] |        |
| Asian                | 0.88 | 0.806–0.954 | 0.002  |
| Black                | 0.60 | 0.522–0.683 | <0.001 |
| Mixed                | 0.66 | 0.521–0.843 | <0.001 |
| Other                | 0.75 | 0.597–0.939 | 0.012  |
| IMD Quintile         |      |          |         |
| 1 (most deprived)    | 0.95 | 0.871–1.044 | 0.300  |
| 2                    | 0.99 | 0.907–1.071 | 0.737  |
| 3                    | 1.00 | 0.922–1.079 | 0.953  |
| 4                    | 1.01 | 0.937–1.088 | 0.795  |
| 5 (least deprived)   | 1.00 | [Reference] |        |
| BMI category (kg/m²)²|      |          |         |
| Underweight          | 0.21 | 0.083–0.549 | 0.001  |
| Normal               | 1.00 | [Reference] |        |
| Overweight           | 2.05 | 1.841–2.274 | <0.001 |
| Obese                | 3.84 | 3.472–4.250 | <0.001 |
| eGFR (mL/min/1.73m²) |      |          |         |
| <45                  | 0.03 | 0.011–0.080 | <0.001 |
| 45–59                | 0.18 | 0.145–0.224 | <0.001 |
| ≥60                  | 1.00 | [Reference] |        |
| Comorbidities        |      |          |         |
| Heart failure        | 0.81 | 0.653–0.998 | 0.048  |
| CVD                  | 0.69 | 0.636–0.739 | <0.001 |
| Other covariates     |      |          |         |
| Systolic BP (mmHg)   | 1.00 | 0.996–0.999 | 0.001  |
| HbA1c (mmol/mol)     | 1.03 | 1.029–1.031 | <0.001 |
| Diuretic             | 0.74 | 0.682–0.804 | <0.001 |

OR odds ratio, BMI body mass index, BP blood pressure, CVD cardiovascular disease, HbA1c glycated haemoglobin, IMD Index of Multiple Deprivation

* BMI categories closest to first SGLT-2i prescription: underweight, <18.5 kg/m²; normal, 18.5–24.9 kg/m²; overweight, 25.0–29.9 kg/m²; obese, ≥30 kg/m²
recommendations with these drugs to use with caution when in combination with diuretics, whereby the risk of dehydration was promoted early in the introduction of the drugs into clinical practice [37]. Our results appear to support this notion, since prescribing of diuretics was also associated with reduced odds of being prescribed SGLT-2is. However, this might be a temporal effect as the benefits within the heart failure group have only recently been incorporated into international (EASD/ADA) guidelines and have yet to be included as part of the treatment algorithm in the UK based NICE guidelines for type 2 diabetes, which focus principally on improving glycaemic control [11, 15]. There is accumulating data on the benefits of SGLT-2is on cardiac function, vascular endothelial function, and cardio-metabolic risk factors [38–43], which may further enhance utilisation of these drugs in real-world clinical practice.

Although current guidelines advise against co-administration SGLT-2is and diuretics to avoid volume depletion [13], proof of concept studies have inferred a possible synergy between the SGLT-2is and diuretics in the management of heart failure in people with type 2 diabetes [12, 44]. For example, in a randomised, open-label, parallel group study of 42 healthy participants treated with once-daily bumetanide, dapagliflozin, or both agents for seven days, followed by both agents over eight days, it was found that sodium excretion was greater when the agents were used in combination than individually. The authors concluded that use of SGLT-2is might be beneficial for use in heart failure, particularly in those with loop diuretic resistance. Despite these potential benefits, it is unknown whether there is any difference in side-effects that may require hospital admission, when taking concomitant diuretic therapy, and whether dual prescribing confers additional heart failure benefits in real-world practice. Further clinical trials are needed to help answer these questions.

Strengths and limitations

The large sample size and wide coverage across England are key strengths of the Oxford-RCGP RSC database. Other benefits of the database include high data quality dating back to 2004, which make it an ideal resource for longitudinal follow-up of patient populations. The Oxford-RCGP RSC network also comprises a broadly representative population in terms of age, sex, and ethnicity compared to England and Wales Census data, although the more deprived population are slightly underrepresented [14]. Additional limitations relate to the secondary use of routinely collected data.

As with all observational data, the Oxford-RCGP RSC database was affected to an extent by missing data. For example, within the computerised medical records, confirmed diagnosed conditions such as heart failure, were indicated by a date field. For analytical purposes, everyone without a date was assumed not to have the condition, when in fact some cases may have had undiagnosed heart failure. In addition, key information about a patient is often recorded in the GP’s notes; data that we did not have access to for these analyses.

For other variables, we were able to use multiple imputation to impute the missing cases in our sensitivity analysis. For the most part, this confirmed the main findings for the analysis of complete cases; the finding that people with Asian ethnicity had higher odds of being prescribed SGLT-2is than White people was most likely due to assigning missing data to the White category.

Conclusions

Prescribing for glucose lowering of SGLT-2is in type 2 diabetes in primary care concurs with the licenced indications according to renal function. A history of heart failure diagnosis has not been incorporated into NICE diabetes management guidelines and current practice reflects this with the low prescription rates in heart failure in type 2 diabetes. It is worth revisiting this analysis again should NICE guidelines be updated to incorporate new data on the benefits of SGLT-2is for those with reduced renal function or with heart failure.

Abbreviations

ADA: American Diabetes Association; BMI: Body mass index; BP: Blood pressure; CANDIS: Canagliflozin Cardiovascular Assessment Study; CREDENCE: Canagliflozin and Renal Events in Diabetes with Established Nephropathy and Cardiovascular Disease; DECLARE-TIMI 58: Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58; EASD: European Association for the Study of Diabetes; eGFR: Estimated glomerular filtration rate; EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose; HbA1c: Glycated haemoglobin; IMD: Index of Multiple Deprivation; NICE: National Institute of for Health Care and Excellence; RCGP RSC: Royal College of General Practitioners Research and Surveillance Centre; SGLT-2i: Sodium-glucose co-transporter-2 inhibitor; SIGN: Scottish Intercollegiate Guidelines Network; SNOMED CT: Systematized Nomenclature of Medicine Clinical Terms; VERTIS-CV: Evaluation of ERtugliflozin efficacy and Safety CardioVascular outcomes trial.

Additional file 1. Appendix 1. 5-byte version 2 Read and CTV3 codes used to identify the presence of heart failure.

Additional file 2. Figure S1. A forest plot of odds ratios for characteristics associated with prescribing of SGLT-2is in people with type 2 diabetes: complete cases. Figure S2. A forest plot of odds ratios for characteristics associated with prescribing of SGLT-2is in people with type 2 diabetes: imputed dataset. Table S1. Prescribing of SGLT-2is in people with type 2 diabetes; multilevel logistic regression model of imputed dataset.
Acknowledgements
The authors would like to thank patients and practices who are members of the Oxford-RCGP RSC network, and the CNiR system vendors: EMIS, In Practice, and TPP. We would also like to thank Apollo Medical systems, the RCGP, and University of Oxford colleagues: Filipa Ferreira (Programme Manager), and Julian Sherlock and Cecilia Okusi (SQL developers).

Authors’ contributions
WH led the drafting of the manuscript and analysed the data. MJ contributed to the statistical analysis. MF, NM, MI, and SL reviewed the manuscript and study design, and contributed to the final manuscript draft. All authors read and approved the final manuscript.

Funding
This study was sponsored by AstraZeneca UK Limited.

Availability of data and materials
The Oxford-RCGP RSC data set can be accessed by researchers; approval is given on a project-by-project basis. Researchers wishing to directly analyse the patient-level pseudonymised data are required to complete information governance training and work on the data from the secure servers at the University of Oxford. Patient-level data cannot be taken out of the secure network.

Declarations

Ethics approval and consent to participate
The study was checked against the Health Research Authority (HRA) Medical Research Council (MRC) tool for identifying research, and was identified as a clinical audit. The study requirements were also checked against the Research Integrity and Governance Office’s (at the University of Surrey) Self-Assessment for Governance and Ethics tool, which confirmed that a formal ethics review was not required for this work. The Oxford-RCGP RSC Study Approval Committee approved this study for access to key variables within the database. Data were pseudonymised at the time of extraction and therefore, personal data were not identifiable to the researchers. Informed consent was not required for this study. As per the UK National Data Guardian consent/opt-out model [45], data were not processed for patients with flags in their records to indicate they opted out of data sharing.

Consent for publication
Informed consent was not required, which is in compliance with the UK National Data Guardian consent/opt-out model.

Competing interests
William Hinton has had part of his academic salary funded from grant awards from Eli Lilly and Company, AstraZeneca, and Novo Nordisk Ltd. Eithan Sherlock and Cecilia Okusi work for the University of Surrey. Julian Sherlock is now with the University of Oxford. Robin Sherlock and Cecilia Okusi are National Data Guardians. They have not had any other financial involvement in the project. All authors declare no other potential conflicts of interest.

Author details
1 Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. 2 Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK. 3 Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC), London, UK.

Received: 15 March 2021 Accepted: 7 June 2021 Published online: 28 June 2021

References
1. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78–89.

2. Goodchild E, Choudhury TA. Managing diabetes in the presence of renal impairment. Prescriber. 2017;28(9):24–30.

3. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyskens S, Maslakiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.

4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Emdur N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

5. Liviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

7. Caffrey M. New VERTIS-CV Analysis Finds Renal Benefits for Ertugliflozin on Par With Other SGLT2s 29 September 2020 [cited 2021 3rd February]. https://www.ajmc.com/view/new-vertis-cv-analysis-finds-renal-benefits-for-ertugliflozin-on-par-with-other-sglt2s.

8. Mosenzon O, Liviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–17.

9. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Emdur N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704.

10. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.

11. Davies MJ, D’Alessio DA, Fradkin J, Keanan WN, Mathieu C, Mongrone G, et al. Management of hyperglycaemia in type 2 diabetes. 2018 A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.

12. Mordi NA, Mordi IR, Singh JS, Baj G, Choy AM, McCreinnon RJ, et al. Renal and cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECIDE-CHF): protocol for a randomised controlled double-blind cross-over trial. BMJ Open. 2017;7(10):e018097.

13. Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9(5):157–73.

14. Correa A, Hinton W, McGovern A, van Wymen J, Youona J, Jones S, et al. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016;6(4):e011092.

15. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline [NG28]. 2015 [cited 2021 12th February]. https://www.nice.org.uk/guidance/ng28.

16. Scottish Intercollegiate Guidelines Network. SIGN 154. Pharmacological management of glycaemic control in people with type 2 diabetes: a national clinical guideline. Edinburgh. 2017 [cited 2021 14th May]. https://www.sign.ac.uk/media/1090/sign154.pdf.

17. Benson T. Why general practitioners use computers and hospital doctors do not—Part 1: incentives. BMJ. 2002;325(7372):1086–9.

18. de Lusignan S. Codes, classifications, terminologies and nomenclatures: definition, development and application in practice. Inform Prim Care. 2005;13(1):65–70.

19. NHS Digital. SNOMED CT in primary care—implementation update. [cited 2021 12th February]. https://digital.nhs.uk/services/terminology- and-classifications/snomed-ct/snomed-ct-implementation-in-prima ry-care/snomed-ct-in-primary-care-implementation-update.

20. McGovern A, Hinton W, Correa A, Munro N, Whyte M, de Lusignan S. Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. BMJ Open. 2016;6(11):e012801.

21. Langdown C, Peckham S. The use of financial incentives to help improve health outcomes: is the quality and outcomes framework fit for purpose? A systematic review. J Public Health (Oxf). 2014;36(2):251–8.

22. Hinton W, Feher M, Munro N, de Lusignan S. Does renal function or heart failure diagnosis affect primary care prescribing for
23. Cole NI, Liyanage H, Suckling RJ, Swift PA, Gallagher H, Byford R, et al. An ontological approach to identifying cases of chronic kidney disease from routine primary care data: a cross-sectional study. BMC Nephrol. 2018;19(1):85.

24. Office for National Statistics. Ethnic group, national identity and religion. Date unknown [cited 2021 19th February]. https://www.ons.gov.uk/methodology/classificationsandstandards/measuringequality/ethnicgroup/pnati onalidentityandreligion#ethnic-group.

25. Tippu Z, Correa A, Liyanage H, Burleigh D, McGovern A, Van Vlymen J, et al. Ethnicity recording in primary care computerised medical record systems: an ontological approach. J Innov Health Inform. 2017;23(4):920.

26. Department for Communities and Local Government. The English indices of deprivation 2015 [cited 2021 19th February]. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015.

27. Pham TM, Carpenter JR, Morris TP, Wood AM, Petersen I. Population-calibrated multiple imputation for a binary/categorical covariate in categorical regression models. Stat Med. 2019;38(5):792–808.

28. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 2004.

29. Pereira MJ, Millar SA, O'Sullivan SE, Idris I. Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies. Diabetes Ther. 2020;11(9):1947–63.

30. Cahill ME, Graham CG, McEniery CM, Underwood RA, Scanlon P, Murphy NE, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

31. Pinto LC, Rados DV, Remonti LR, Kramer CK, Leitao CB, Gross JL. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2018;10(1):70–80.

32. Game F. Novel hypoglycemic agents: considerations in patients with chronic kidney disease. Nephron Clin Pract. 2014;126(1):14–8.

33. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Cardiovascular outcomes with the sodium-glucose co-transporter 2 inhibitor dapagliflozin versus sitagliptin in patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1.

34. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;61:81–83.

35. Napp Pharmaceuticals announces European Commission approval of Invokana® (canagliflozin) label update to reflect improved renal outcomes in patients with diabetic kidney disease and type 2 diabetes [cited 2021 25th February]. https://napp.co.uk/secondary_news/napp-pharmaceuticals-announces-european-commission-approval-of-invokana-canagliflozin-label-update/.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.